Evercore ISI Group Maintains Outperform on Immunome, Raises Price Target to $40

Benzinga · 23h ago
Evercore ISI Group analyst Cory Kasimov maintains Immunome (NASDAQ:IMNM) with a Outperform and raises the price target from $18 to $40.